title: Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems.
abstract: We investigated the efficacy of two different tissue plasminogen activators (t-PA) for preventing vasospasm after experimental subarachnoid hemorrhage (SAH) in rabbits. Intrathecal injection of Silteplase and Alteplase showed significant preventive action against vasospasm following SAH and thrombolytic effect. The low dose groups with both t-PA showed more preventive action on day 1 than the high dose groups. The data suggest that the determination of optimum dose of t-PA is essential in clinical use of t-PA.
authors.affiliation: Department of Neurosurgery, Kobe University School of Medicine, Hyougo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Asada
authors.forename: J
authors.initials: J
authors.lastname: Kong
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: N
authors.initials: N
authors.lastname: Tamaki
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007278:Injections, Spinal; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D010960:Plasminogen Activators / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D013345:Subarachnoid Hemorrhage / Q000150:complications*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; C105533:Silteplase; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator